Emily Feld is an Oncology physician. OpenAlex indexes 25 publications with 1,264 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Civic Center Blvd
Perelman Center South Pavilion, Room 10-134
Philadelphia, PA 19104
Telephone
215-662-3681Provider last certified this registry record 24 Jun 2020.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20252 payments
- Astellas Pharma US IncProgram year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.7%Cytochrome P450 17A1 Inhibitor18.2%Abiraterone Acetate100%Part D≥35 patientsKinase inhibitor7.9%Lenvima45%Everolimus28%Cabometyx27%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
26.7%Corticosteroid18.5%Prednisone100%Part D≥51 patientsSerotonin-3 Receptor Antagonist3.1%Ondansetron Hcl100%Part D≥27 patients+ 3 more classes in this area
Sensory organs
6.3%Corticosteroid6.3%Dexamethasone Sodium Phosphate50%Dexamethasone34%Clobetasol Propionate16%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
European Urology Oncology
2023 - A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma.
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”